ClinicalTrials.gg
CompletedNCT06872151Updated Jul 2, 2025

Evaluation of the Effectiveness of a Topical Medical Device in Wound Healing and Symptom Relief in the Postoperative Period of Open Excisional Hemorrhoidectomy (The Emor Study)

A Phase 4 interventional study of Gel containing a Propionibacterium extract and Hyaluronic acid and silver sulfadiazine in Anus Diseases, Gastrointestinal Diseases and Intestinal Diseases, sponsored by University of Cagliari. Completed at 1 site in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-02.

Primary conditionHemorrhoidsRegistry: Gastrointestinal DiseasesReclassifiedWhy we changed it
Registry
Gastrointestinal Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hemorrhoids
Why
  1. The study's listed conditions name Hemorrhoids, a narrower term within Gastrointestinal Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Cagliari · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Hemorrhoids with a site in Italy — 3 open to participants now, 3 under way, none of them phase 3. Hemorrhoids · Italy.

Enrollment
5th of 11
114 · median 105
Started
2025
with 2 others
Phase 4
3 of 15
none open now
Registered
12th of 15
by date
Lead sponsor
1 of 15
University of Cagliari

Among the 15 studies in Hemorrhoids with a site in Italy, this one is the 5th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2025, is one of 3 in phase 4, and was the 12th registered.

Hemorrhoids

240 studies on the registry are indexed under Hemorrhoids; 73 are open to participants now.

Browse Hemorrhoids studies →

Open to participants now

3 of the 15 studies in Hemorrhoids with a site in Italy are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 38 Hemorrhoids studies recruiting now, 15 (39%) set no upper age limit and 11 (29%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hemorrhoids with a site in Italy, or all of them as a file.
02

Study summary

This multicenter randomized controlled phase IV trial aims to compare the clinical efficacy of a gel containing a Propionibacterium extract and a gel with hyaluronic acid and silver sulfadiazine in the degree of epithelialization of post-operative wounds of open excisional hemorrhoidectomy.

The main questions it aims to answer are:

  • To compare the efficacy of the two medical devices in the degree of epithelialization in the postoperative period of open excisional hemorrhoidectomy, at 0, 10, 20 and 40 days from the beginning of treatment.
  • To evaluate the effectiveness of these devices in alleviating: pain, itching, burning, and the type of bowel habit Participants will be randomized, at the beginning of the study, to one of the two treatments, and the efficacy of the two medical devices will be evaluated at 0, 10, 20 and 40 days from the start of treatment.
03

Conditions studied

  • Anus Diseases
  • Gastrointestinal Diseases
  • Intestinal Diseases
  • Cicatrization
  • Hemorrhoids
  • Hemorrhoids Third Degree

Browse trials for

Keywords

  • hemorrhoids
  • epithelialization
  • Anal diseases
  • hemorrhoidectomy
04

In context

Hemorrhoids Reclassified

240 studies on the registry are indexed under Hemorrhoids; 73 are open to participants now.

This study's enrollment of 114 is above the median of 100 across 185 interventional studies indexed under Hemorrhoids.

Browse Hemorrhoids studies →

Lead sponsor

University of Cagliari is the lead sponsor of 85 studies on the registry; 17 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.

Compared within Hemorrhoids, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Gastrointestinal Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Open excisional hemorrhoidectomy, with removal of at least 3 groups
  • Age between 18 and 75 years

Exclusion criteria

Exclusion Criteria:

  • Patients who do not consent to the study
  • Opioid-dependent patients, chronic use of analgesics
  • Fecal incontinence
  • Anorectal neoplasms
  • treatments (e.g., chemotherapy, radiotherapy, etc.)
  • Chronic inflammatory bowel diseases
  • Pregnancy
  • Patients with major psychiatric disorders
  • Known allergy to the components of the treatments under study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    Gel containing a Propionibacterium extract

    Device: Gel containing a Propionibacterium extract

  • Active comparator
    Hyaluronic acid and silver sulfadiazine

    Drug: Hyaluronic acid and silver sulfadiazine

Interventions

  • DeviceGel containing a Propionibacterium extract

    Patients will apply 1 ml of gel (equal to one phalanx) twice a day for 20 days, manually at the anal level and in the perianal area. In the morning, after defecation and in the evening before going to bed.

  • DrugHyaluronic acid and silver sulfadiazine

    Drug pages: Hyaluronic AcidStudies of Hyaluronic AcidHyaluronic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Silver SulfadiazineStudies of Silver SulfadiazineSilver Sulfadiazine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will apply 1ml of gel (equal to a phalanx) twice a day for 20 days, manually at the anal level and in the perianal area. In the morning, after defecation and in the evening before going to bed.

07

What researchers measure

Primary outcomes

  1. Degree of epithelialization

    The degree of epithelialization of the fissure was determined at each visit and stratified using 3 levels (1 to 3) corresponding to: 1. \< 50% 2. \> 50% 3. 100% (complete healing)

    Time frame: From baseline to visit 3 (40 days after the start of the treatment)

Secondary outcomes

  1. Burning and pain

    Visual analogue scale (VAS) (minimum score = 0, maximum score = 10)

    Time frame: From baseline to visit 3 (40 days after the start of the treatment)

  2. Itching

    Visual analogue scale (VAS) (minimum score = 0, maximum score = 10)

    Time frame: From baseline to visit 3 (40 days after the start of the treatment)

  3. Bowel movements

    Bristol Scale (minimum score =1, maximum score =7)

    Time frame: At visit 3 (40 days after the start of the treatment)

08

Study locations

1 site
  • Policlinico Universitario Monserrato "Duilio Casula" - AOU Cagliari
    Monserrato, Cagliari 09042, Italy
09

References and documents

Publications

  • Deidda S, Eberspacher C, Argiolas V, Ventrone L, Testa A, Ascanelli S, Rossin E, Lisi G, Mascagni D, Zorcolo L. Evaluation of the efficacy of a Propionibacterium extract gel in wound healing and symptom relief after open excisional hemorrhoidectomy: a randomized clinical study. Tech Coloproctol. 2026 Jun 23. doi: 10.1007/s10151-026-03381-x. Online ahead of print. PubMed 42334667 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2025 to primary completion in Mar 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2025
First posted
Mar 12, 2025
StartActual
Mar 4, 2025
Primary completionActual
Mar 4, 2025
CompletionActual
May 30, 2025
Last update
Jul 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06872151
Lead sponsor
University of Cagliari
Collaborators
Azienda Policlinico Umberto I, Hospital San Pietro Fatebenefratelli, University Hospital of Ferrara, ASL Roma 6
Responsible party
Simona Deidda (Assistant professor, University of Cagliari) — Principal investigator
First posted
Mar 12, 2025
Start date
Mar 4, 2025
Primary completion
Mar 4, 2025
Completion
May 30, 2025
Last update
Jul 2, 2025

Study contacts

Deidda
principal investigator · University of Cagliari

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion